News
Guides, lab handling, storage and research insights from our team.
FDA approval
Aug 07, 2026
Retatrutide vs. Tirzepatide for Obesity Decline: Addressing GLP-1 Misuse Risks Highlighted by DoctorsRetatrutide and tirzepatide are two peptides studied for obesity, but only tirzepatide is FDA-approved. Doctors warn about misuse risks of...Read article
alcohol use disorder
Aug 05, 2026
Retatrutide in VA Alcohol Use Disorder Trials: Could the Triple-Agonist Outperform Tirzepatide for Veterans?The VA is testing retatrutide, a triple-agonist peptide, for alcohol use disorder. Could it outperform tirzepatide? This article examines the...Read article
compounding
Jul 29, 2026
Retatrutide and the FDA Peptide Panel Vote: Could Triple-Agonist Compounding Outlast Tirzepatide Shortages?The FDA's peptide panel vote could reshape compounding access for retatrutide, a triple-agonist still in trials. As tirzepatide shortages persist,...Read article
GLP-1 agonists
Jul 24, 2026
Retatrutide for Post-Ramadan Weight RegainRetatrutide, an investigational triple agonist, may help mitigate semaglutide resumption intolerance after Ramadan. This article examines the regulatoryRead article
GIP
Jul 22, 2026
Tirzepatide vs. Retatrutide for Menstrual Cycle ChangesTirzepatide and retatrutide are incretin-based therapies with different receptor targets. This article examines their potential effects on menstrual cyclesRead article